+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dynavax Technologies Corporation - logo

Dynavax is a clinical-stage biopharmaceutical company with multiple product candidates in development for the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The company’s lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine; and AZD1419, which is in Phase II clinical trial for the treatment of asthma. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

From
From
Collaboration Deals in Pharmaceuticals 2019-2025 - Product Thumbnail Image

Collaboration Deals in Pharmaceuticals 2019-2025

  • Report
  • April 2025
  • 950 Pages
  • Global
From
Cancer Vaccines Market Report 2025 - Product Thumbnail Image

Cancer Vaccines Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
From
From
From
From
Sexually Transmitted Diseases (STD) Treatment Market 2024-2028 - Product Thumbnail Image

Sexually Transmitted Diseases (STD) Treatment Market 2024-2028

  • Report
  • October 2024
  • 145 Pages
  • Global
From
B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2025 - Product Thumbnail Image

B-Cell Chronic Lymphocytic Leukemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Liver Fibrosis Market - Product Thumbnail Image

Liver Fibrosis Market

  • Report
  • January 2025
  • 250 Pages
  • Global
From
Acute Pancreatitis Market Report 2025 - Product Thumbnail Image

Acute Pancreatitis Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Loading Indicator